Hottest Healthcare Stocks Short-Term Price Target Review: KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)

healthcare

KBIO: 39.50 +21.25 (116.44%)

On Thursday, in the course of Hot Morning trade, shares of KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) inclined +419.81% or +8.47 points.

After the declaration of this news, the firm opened its current trade at $14.00. The stock is now trading at $10.74, floating in a range of $11.12 $14.72. The total volume traded for the day is 3.97M  shares, as of now, lower than its average daily volume of 608,620.00 shares. The stock’s 52-week range remained $0.44 $16.00.

Martin Shkreli, chief investment officer of MSMB Capital Administration.

Late Thursday night, the pharmaceutical company KaloBios revealed that an investor group involving Shkreli attained more than half of the companys outstanding stock and was in negotiations to keep the company in operation, according to Business Insider

As a result, shares of KaloBios were up more than 600% in premarket trade on Thursday.

Shortly after the market open, the stock was up about 480%.

KaloBios had said in a release on Friday that it was going to wind down its operations and stop the development of the two drugs it was working on. Business Insider Report

On Nov. 18, KaloBios Pharmaceuticals, Inc. (KBIO) declared that it has been informed that an investor group comprised of Martin Shkreli and associates together have attained more than 50% of the outstanding shares of KaloBios, and that the company is in negotiations with Mr. Shkreli regarding possible direction for the company to continue in operation. Mr. Shkreli is the founder and chief executive officer of Turing Pharmaceuticals, a privately held biopharmaceutical company.

Short-Term Price Target Review:

In addition to major news, short-term price target update for KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) is available.
The mean estimate for the short-term price target for the firm stands at $5.00, according to 1 brokers. The higher price target for BIDU is $5.00, while the lower price target is $5.00. In the past 52-weeks, the company shares have declined -25.47% and marked new low $0.44 on Nov 16, 2015.

Analysts mean recommendation for the stock is 1.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of monoclonal antibody therapeutics for diseases that represent a burden to society and to patients and their families. The Company operates through the development of pharmaceutical products segment. The Company seeks to identify and develop products that may treat multiple indications through proof of concept studies. The Companys principal pharmaceutical product candidates comprise: KB004, KB003 and KB001‑A. KB004 is a Humaneered anti EphA3 monoclonal antibody that has the potential to offer an approach to treating both hematologic malignancies and solid tumors. KB003 is a Humaneered anti granulocyte macrophage colony stimulating factor monoclonal antibody that was developed for the treatment of severe asthma.

DISCLAIMER:

This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.

Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.

Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.

Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.

You may also like

Afternoon Alert: Aetna Inc (NYSE:AET), Fire Eye In…Afternoon stocks overview: American Airlines Group…Afternoon Stocks Alert: Bio Marin Pharmaceutical I…Afternoon Trade Watch: Builders First Source, Inc….Afternoon Trade buzz: Anavex Life Sciences Corp. (…Active Stocks: Anadarko Petroleum Corporation (NYS…Remarkable Stocks Buzz: NVIDIA Corporation (NASDAQ…These Stocks: Mann Kind Corporation (NASDAQ:MNKD),…Remarkable Trending Stocks: Met life Inc (NYSE:MET…

About Travis Garlick 1742 Articles
Been writing about and trading stocks since 2013. Manage a group of micro-cap investors on Facebook with over 15,000 members. Turned $8,500 into 185k the first year I started trading stocks and haven't looked back.